BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The European School of Multimodality Imaging & Therapy (ESMIT) - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://esmit.eanm.org
X-WR-CALDESC:Events for The European School of Multimodality Imaging & Therapy (ESMIT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20240906T133000
DTEND;TZID=Europe/Vienna:20240906T143000
DTSTAMP:20260422T063227
CREATED:20240213T191555Z
LAST-MODIFIED:20240710T090914Z
UID:1291-1725629400-1725633000@esmit.eanm.org
SUMMARY:FDG-PET/CT in Breast Cancer
DESCRIPTION:Breast cancer is the most common cancer in women worldwide and it is still one of the leading causes of morbi-mortality\, therefore being a major concern. 2-[18F]FDG PET/CT is commonly used in the clinical management of patients with breast cancer\, with significant impact on clinical management. Currently\, there is robust evidence supporting the usefulness of 2-[18F]FDG PET/CT in the initial staging of patients with locally advanced and metastatic breast cancer\, in the early assessment of treatment response and in the early detection of recurrence. The first presentation of this webinar will summarize the recently published “Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer” which was endorsed by other relevant societies in the subject of breast cancer (ACR\, ESSO\, ESTRO\, EUSOBI/ESR\, and EUSOMA). Updated information to support the recommendations to perform 2-[18F]FDG PET/CT in no special type breast cancer in different clinical settings will be provided. Despite no special type breast cancer presenting high 2-[18F]FDG avidity\, other breast cancer subtypes seem to be better evaluated with other PET radiopharmaceuticals. Therefore\, the second presentation will address the potential role of [18F]FES\, [89Zr]Trastuzumab\, [18F]Sodium fluoride (NaF)\, [18F]Fluciclovine (FACBC)\, [89Zr]Pembrolizumab and FAPI-ligands in breast cancer. During this webinar we want to brainstorm about the role of PET/CT in the different subtypes and clinical scenarios of patients with breast cancer. The webinar will be enriched by interactive clinical case discussion\, aiming to resemble the challenges found in daily clinical practice. \n\n\n\nLearning Objectives:  \n\n\n\n\nGeneral aspects to avoid false positive and false negative findings on 2-[18F]FDG PET/CT.\n\n\n\nDiagnostic accuracy of 2-[18F]FDG PET/CT compared to conventional imaging modalities.\n\n\n\nRecommendations for performing 2-[18F]FDG PET/CT in the initial staging\, in assessing response to therapy and in assessing recurrence.\n\n\n\nAppropriate PET radiopharmaceuticals to better address each breast cancer subtype.\n\n\n\nSpecific characteristics\, physiological biodistribution\, advantages and disadvantages of PET radiopharmaceuticals used in breast cancer beyond 2-[18F]FDG.\n\n\n\nGeneral interpretation criteria to optimize the information provided in the final PET/CT report.\n\n\n\n\n\n\n\n\nSave yourself a FREE seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now FOR FREE!\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nLioe-Fee de Geus-OeiModeratorLeiden\, Netherlands \n\n\n\n\n\nSofia VazSpeakerLisbon\, Portugal \n\n\n\n\n\nLidija AntunovicSpeakerMilan\, Italy \n\n\n\n\n\n\n\n\n\nRegistration\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\neLearning Course StoreEnter the course store\, make your selection and check out. \n\n\n\nEnroll yourselfFind your desired webinar under ‘Single Webinar Tickets’ or enroll for all 2024 webinars with the eLearning Access Plan – FREE OF CHARGE \n\n\n\nEnjoy!The link for the Zoom Webinar will be made available to you on the eLearning platform in the course contents \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/fdg-pet-ct-in-breast-cancer/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20240920T133000
DTEND;TZID=Europe/Vienna:20240920T143000
DTSTAMP:20260422T063227
CREATED:20240213T192107Z
LAST-MODIFIED:20240731T083213Z
UID:1294-1726839000-1726842600@esmit.eanm.org
SUMMARY:Paediatric Nuclear Medicine in Nephro-Urology
DESCRIPTION:The webinar will cover the most relevant methodological aspects of nuclear medicine techniques in paediatric nephrourology\, with particular attention to the choice of the radiotracer\, the correct patient preparation\, and the acquisition protocol. Some typical cases will show the main points of image processing and results visualization. The clinical part will deal with hydronephrosis and hydroureteronephrosis\, spacing from typical pelvicureteral junction obstruction to obstructive megaureter\, and some complex malformations\, such as duplex kidneys. The selected cases will pinpoint the critical clues used in interpreting and reporting the scintigraphic studies and the integration of scintigraphic data with other imaging modalities (ultrasounds\, MRI\, etc.) in evaluating paediatric nephrourology patients. \n\n\n\nLearning Objectives: The aim of this course is to review the methodology and the main indications for scintigraphic studies in paediatric nephro-urology\, taking into accounts the more relevant and recent international guidelines and offering various examples taken from the current clinical practice. \n\n\n\nSuggested Readings:1. The SNMMI and EANM Procedural Guidelines for Diuresis Renography in Infants and Children2. EANM procedural recommendations for managing the paediatric patient diagnostic nuclear medicine \n\n\n\n\n\n\n\nSave yourself a FREE seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now FOR FREE!\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nDiego CecchinModeratorPadua\, Italy \n\n\n\n\n\nPietro ZucchettaSpeakerPadua\, Italy \n\n\n\n\n\n\n\n\n\nRegistration\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\neLearning Course StoreEnter the course store\, make your selection and check out. \n\n\n\nEnroll yourselfFind your desired webinar under ‘Single Webinar Tickets’ or enroll for all 2024 webinars with the eLearning Access Plan – FREE OF CHARGE \n\n\n\nEnjoy!The link for the Zoom Webinar will be made available to you on the eLearning platform in the course contents \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/paediatric-nuclear-medicine-in-nephro-urology/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
END:VCALENDAR